{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:36:08Z","timestamp":1790912168072,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In the TRANSCEND FL primary analysis, lisocabtagene maraleucel (liso-cel) showed high response rates and favorable safety in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL). Longer follow-up is needed to assess remission durability and long-term or late-onset toxicities. Here, we report 3-year follow-up results (median on-study follow-up, 41.5 months [range, 0.3-54.0]) in patients with third-line or later (3L+) FL. Patients had R\/R FL after \u22652 previous lines of combination systemic therapy, including an anti-CD20 antibody and an alkylator. A total of 107 patients received liso-cel and 103 were efficacy evaluable, with overall and complete response rates per independent review committee of 97% (95% confidence interval [CI], 92-99) and 94% (95% CI, 88-98), respectively. Medians were not reached for all time-to-event outcomes; estimated 36-month rates for duration of response, progression-free survival, time free from next treatment, and overall survival were 70% (95% CI, 60-78), 68% (95% CI, 58-76), 75% (95% CI, 70-80), and 86% (95% CI, 78-92), respectively. Response rates and 36-month time-to-event rates were consistent in high-risk subgroups, including patients with disease progression within 24 months of starting first-line immunochemotherapy, bulky disease, or double-refractory status. Longitudinal safety analyses showed decreasing grade \u22653 cytopenias and hypogammaglobulinemia (immunoglobulin G &amp;lt;500 mg\/dL), with use of supportive care (transfusions, growth factors, IV immunoglobulin) mostly limited to the 3 months after infusion, and consistently low incidences of grade \u22653 infections in short- and long-term periods. At 3-year follow-up, a single liso-cel infusion delivered durable efficacy and high survival, including in high-risk subgroups, alongside a favorable long-term safety profile in patients with 3L+ FL. This trial was registered at www.clinicaltrials.gov as NCT04245839.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026034327","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:25:56Z","timestamp":1784226356000},"page":"1789-1799","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"first","affiliation":[{"name":"1Department of Lymphoma\/Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1028","authenticated-orcid":false,"given":"Alejandro","family":"Mart\u00edn Garc\u00eda-Sancho","sequence":"additional","affiliation":[{"name":"2Hospital Universitario de Salamanca, IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6408-1747","authenticated-orcid":false,"given":"Juan Luis","family":"Reguera Ortega","sequence":"additional","affiliation":[{"name":"3Hospital Universitario Virgen del Roc\u00edo, Instituto de Biomedicina de Sevilla\/CSIC, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"4Montpellier University Hospital Center, UMR CNRS 5535, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"6National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[{"name":"7H\u00f4pital Lyon Sud, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[{"name":"8Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"9Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"10Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"11Department of Internal Medicine, Universit\u00e4t zu K\u00f6ln, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-1062","authenticated-orcid":false,"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-152X","authenticated-orcid":false,"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-5249","authenticated-orcid":false,"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"14Klinikum der Universit\u00e4t, LMU M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"14Klinikum der Universit\u00e4t, LMU M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"15Division of Blood and Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA"},{"name":"16University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"17Southwest Oncology, CommonSpirit Mercy, Durango, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Bar","sequence":"additional","affiliation":[{"name":"18Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Strocchia","sequence":"additional","affiliation":[{"name":"18Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3309-9006","authenticated-orcid":false,"given":"Martina","family":"Raggi","sequence":"additional","affiliation":[{"name":"18Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Bueno","sequence":"additional","affiliation":[{"name":"18Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Papuga","sequence":"additional","affiliation":[{"name":"18Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0262-6280","authenticated-orcid":false,"given":"Silvia","family":"Colicino","sequence":"additional","affiliation":[{"name":"18Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"19Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2026100111263293300_bib1","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"2026100111263293300_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026100111263293300_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"2026100111263293300_bib4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026100111263293300_bib5","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"11","key":"2026100111263293300_bib6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"10254","key":"2026100111263293300_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"2026100111263293300_bib8","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026100111263293300_bib9","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10402","key":"2026100111263293300_bib10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"2026100111263293300_bib11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10532","key":"2026100111263293300_bib12","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(25)02435-3","article-title":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study","volume":"407","author":"Palomba","year":"2026","journal-title":"Lancet"},{"key":"2026100111263293300_bib13","volume-title":"BREYANZI (lisocabtagene maraleucel). Package insert","year":"2024"},{"issue":"27","key":"2026100111263293300_bib14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026100111263293300_bib15","unstructured":"National Comprehensive Cancer Network. B-cell lymphomas (Version 4.2026). Accessed 6 August 2026. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"issue":"3","key":"2026100111263293300_bib16","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous Markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Statist"},{"key":"2026100111263293300_bib17","author":"Pintilie","year":"2006"},{"issue":"suppl 1","key":"2026100111263293300_bib18","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2024-198509","article-title":"Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): TRANSCEND FL 2-year follow-up [abstract]","volume":"144","author":"Nastoupil","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026100111263293300_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026100111263293300_bib20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood-2023-180936","article-title":"Clinical outcomes of patients with relapsed\/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 ELARA 3-year follow-up [abstract]","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"issue":"17","key":"2026100111263293300_bib21","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026100111263293300_bib22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026100111263293300_bib23","first-page":"314","article-title":"Long-term efficacy and survival outcomes with odronextamab for patients (pts) with relapsed\/refractory follicular lymphoma (R\/R FL): 2-year follow-up from the phase 2 ELM-2 study","volume":"9","author":"Luminari","year":"2025","journal-title":"Hemasphere"},{"issue":"suppl 3","key":"2026100111263293300_bib24","article-title":"Epcoritamab monotherapy demonstrates deep and durable responses at 3-year follow-up in patients with relapsed\/refractory follicular lymphoma","volume":"43","author":"Linton","year":"2025","journal-title":"Hematol Oncol"},{"key":"2026100111263293300_bib25","first-page":"288","article-title":"Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R\/R FL after \u22653 years of follow-up: subgroup analysis of a pivotal phase II study","volume":"8","author":"Assouline","year":"2024","journal-title":"Hemasphere"},{"issue":"11","key":"2026100111263293300_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41408-021-00574-5","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018","volume":"11","author":"Dinnessen","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"2026100111263293300_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2017.06.028","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a United States population-based study","volume":"17","author":"Giri","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 16","key":"2026100111263293300_bib28","doi-asserted-by":"crossref","first-page":"7026","DOI":"10.1200\/JCO.2025.43.16_suppl.7026","article-title":"Optimizing post\u2013chimeric antigen receptor (CAR) T cell monitoring: evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"issue":"23","key":"2026100111263293300_bib29","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/bloodadvances.2024013254","article-title":"OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R\/R LBCL","volume":"8","author":"Linhares","year":"2024","journal-title":"Blood Adv"},{"issue":"20","key":"2026100111263293300_bib30","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","article-title":"Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv"},{"key":"2026100111263293300_bib31","author":"Thieblemont","year":"17-21  2025"},{"issue":"suppl 1","key":"2026100111263293300_bib32","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2025-3588","article-title":"Efficacy and safety of long-term odronextamab treatment in patients with relapsed\/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study [abstract]","volume":"146","author":"Villasboas Bisneto","year":"2025","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/14\/1789\/2593375\/blood_bld-2026-034327-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/14\/1789\/2593375\/blood_bld-2026-034327-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:26:40Z","timestamp":1790868400000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/14\/1789\/569473\/Durable-efficacy-and-manageable-long-term-safety"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":32,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026034327","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,1]]},"published":{"date-parts":[[2026,10,1]]}}}